Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers

Journal of Immune Based Therapies and Vaccines

Volumn 6, Issue , 2008, Pages

  Cooper, Curtis L ^a   Ahluwalia, Navneet K ^b   Efler, Susan M ^b   Vollmer, Jörg ^c   Krieg, Arthur M ^c   Davis, Heather L ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Coley Pharmaceutical Canada ^*  (Canada)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE A; CPG OLIGODEOXYNUCLEOTIDE B; CPG OLIGODEOXYNUCLEOTIDE C; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; GENETIC HETEROGENEITY; HEPATITIS C; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL;

EID: 45949092349     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-6-3     Document Type: Article

References (63)

1. Hughes CA Shafran SD Chronic hepatitis C virus management: 2000-2005 update Ann Pharmacother 2006, 40:74-82. 16368925
2. McHutchison JG Bacon BR Chronic hepatitis C: An age wave of disease burden Am J Manag Care 2005, 11:S286-95; quiz S307-11. 16232012
3. Marrone A Sallie R Genetic heterogeneity of hepatitis C virus. The clinical significance of genotypes and quasispecies behavior Clin Lab Med 1996, 16:429-449. 8792081
4. Kanto T Hayashi N Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity Intern Med 2006, 45:183-191. 10.2169/internalmedicine.45.1530 16543687
5. Thimme R Lohmann V Weber F A target on the move: Innate and adaptive immune escape strategies of hepatitis C virus Antiviral Res 2006, 69:129-141. 10.1016/j.antiviral.2005.12.001 16413618
6. Bain C Fatmi A Zoulim F Zarski JP Trepo C Inchauspe G Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection Gastroenterology 2001, 120:512-524. 10.1053/gast.2001.21212 11159892
7. Wong DK Dudley DD Afdhal NH Dienstag J Rice CM Wang L Houghton M Walker BD Koziel MJ Liver-derived CTL in hepatitis C virus infection: Breadth and specificity of responses in a cohort of persons with chronic infection J Immunol 1998, 160:1479-1488. 9570570
8. Botarelli P Brunetto MR Minutello MA Calvo P Unutmaz D Weiner AJ Choo QL Shuster JR Kuo G Bonino F T-lymphocyte response to hepatitis C virus in different clinical courses of infection Gastroenterology 1993, 104:580-587. 8425701
9. Koziel MJ The role of immune responses in the pathogenesis of hepatitis C virus infection J Viral Hepat 1997, 4(Suppl 2):31-41. 10.1111/ j.1365-2893.1997.tb00178.x 9429208
10. Nelson DR Marousis CG Ohno T Davis GL Lau JY Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C Hepatology 1998, 28:225-230. 10.1002/hep.510280129 9657116
11. Kamal SM Fehr J Roesler B Peters T Rasenack JW Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C Gastroenterology 2002, 123:1070-1083. 10.1053/gast.2002.36045 12360469
12. Cramp ME Rossol S Chokshi S Carucci P Williams R Naoumov NV Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C Gastroenterology 2000, 118:346-355. 10.1016/S0016-5085(00)70217-4 10648463
13. Pawlotsky JM Therapy of hepatitis C: From empiricism to eradication Hepatology 2006, 43:S207-20. 10.1002/hep.21064 16447262
14. Theofilopoulos AN Baccala R Beutler B Kono DH Type I interferons (alpha/ beta) in immunity and autoimmunity Annu Rev Immunol 2005, 23:307-336. 10.1146/annurev.immunol.23.021704.115843 15771573
15. Dixit NM Perelson AS The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus Cell Mol Life Sci 2006, 63:832-842. 10.1007/s00018-005-5455-y 16501888
16. Gish RG Treating HCV with ribavirin analogues and ribavirin-like molecules J Antimicrob Chemother 2006, 57:8-13. 10.1093/jac/dki405 16293677
17. Tang KH Herrmann E Cooksley H Tatman N Chokshi S Williams R Zeuzem S Naoumov NV Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy J Hepatol 2005, 43:776-782. 10.1016/j.jhep.2005.05.024 16139918
18. Scott LJ Perry CM Interferon-alpha-2b plus ribavirin: A review of its use in the management of chronic hepatitis C Drugs 2002, 62:507-556. 10.2165/00003495-200262030-00009 11827565
19. Herrmann E Lee JH Marinos G Modi M Zeuzem S Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon Hepatology 2003, 37:1351-1358. 10.1053/jhep.2003.50218 12774014
20. Barnes E Salio M Cerundolo V Medlin J Murphy S Dusheiko G Klenerman P Impact of alpha interferon and ribavirin on the function of maturing dendritic cells Antimicrob Agents Chemother 2004, 48:3382-3389. 514729 15328100 10.1128/AAC.48.9.3382-3389.2004
21. Martin J Navas S Quiroga JA Pardo M Carreno V Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients Cytokine 1998, 10:635-644. 10.1006/cyto.1997.0333 9722937
22. Tam RC Pai B Bard J Lim C Averett DR Phan UT Milovanovic T Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile J Hepatol 1999, 30:376-382. 10.1016/S0168-8278(99)80093-2 10190717
23. Rigopoulou EI Abbott WG Williams R Naoumov NV Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus Antiviral Res 2007, 75:36-42. 10.1016/ j.antiviral.2006.11.008 17210188
24. Feld JJ Hoofnagle JH Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 2005, 436:967-972. 10.1038/nature04082 16107837
25. Vollmer J Rankin R Hartmann H Jurk M Samulowitz U Wader T Janosch A Schetter C Krieg AM Immunopharmacology of CpG oligodeoxynucleotides and ribavirin Antimicrob Agents Chemother 2004, 48:2314-2317. 415599 15155243 10.1128/AAC.48.6.2314-2317.2004
26. Creagh EM O'Neill LA TLRs, NLRs and RLRs: A trinity of pathogen sensors that co-operate in innate immunity Trends Immunol 2006, 27:352-357. 10.1016/j.it.2006.06.003 16807108
27. Iwasaki A Medzhitov R Toll-like receptor control of the adaptive immune responses Nat Immunol 2004, 5:987-995. 10.1038/ni1112 15454922
28. Krieg AM Therapeutic potential of Toll-like receptor 9 activation Nat Rev Drug Discov 2006, 5:471-484. 10.1038/nrd2059 16763660
29. Ballas ZK Rasmussen WL Krieg AM Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA J Immunol 1996, 157:1840-1845. 8757300
30. Hartmann G Weeratna RD Ballas ZK Payette P Blackwell S Suparto I Rasmussen WL Waldschmidt M Sajuthi D Purcell RH Davis HL Krieg AM Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo J Immunol 2000, 164:1617-1624. 10640783
31. Sivori S Carlomagno S Moretta L Moretta A Comparison of different CpG oligodeoxynucleotide classes for their capability to stimulate human NK cells Eur J Immunol 2006, 36:961-967. 10.1002/eji.200535781 16525994
32. Siegal FP Kadowaki N Shodell M Fitzgerald-Bocarsly PA Shah K Ho S Antonenko S Liu YJ The nature of the principal type 1 interferon-producing cells in human blood Science 1999, 284:1835-1837. 10.1126/science.284.5421.1835 10364556
33. Racila DM Kline JN Perspectives in asthma: Molecular use of microbial products in asthma prevention and treatment J Allergy Clin Immunol 2005, 116:1202-1205. 10.1016/j.jaci.2005.08.050 16337446
34. Vollmer J TLR9 in health and disease Int Rev Immunol 2006, 25:155-181. 10.1080/08830180600743107 16818370
35. Asselin-Paturel C Brizard G Chemin K Boonstra A O'Garra A Vicari A Trinchieri G Type I interferon dependence of plasmacytoid dendritic cell activation and migration J Exp Med 2005, 201:1157-1167. 2213121 15795237 10.1084/jem.20041930
36. Gursel M Verthelyi D Gursel I Ishii KJ Klinman DM Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide J Leukoc Biol 2002, 71:813-820. 11994506
37. Krug A Rothenfusser S Hornung V Jahrsdorfer B Blackwell S Ballas ZK Endres S Krieg AM Hartmann G Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells Eur J Immunol 2001, 31:2154-2163. 10.1002/ 1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U 11449369
38. Vollmer J Weeratna R Payette P Jurk M Schetter C Laucht M Wader T Tluk S Liu M Davis HL Krieg AM Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities Eur J Immunol 2004, 34:251-262. 10.1002/eji.200324032 14971051
39. Bernasconi NL Onai N Lanzavecchia A A role for Toll-like receptors in acquired immunity: Up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells Blood 2003, 101:4500-4504. 10.1182/blood-2002-11-3569 12560217
40. Hartmann G Battiany J Poeck H Wagner M Kerkmann M Lubenow N Rothenfusser S Endres S Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells Eur J Immunol 2003, 33:1633-1641. 10.1002/eji.200323813 12778481
41. Marshall JD Fearon K Abbate C Subramanian S Yee P Gregorio J Coffman RL Van Nest G Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions J Leukoc Biol 2003, 73:781-792. 10.1189/jlb.1202630 12773511
42. Krieg A Davis H CpG ODN as a TH1 immune enhancer for prophylactic and therapeutic vaccines. In: Hackett CJ, Harn DA, eds Vaccines Adjuvants: Immunological and Clinical Principles Humana Press Inc 2005:87-110.
43. Cooper CL Davis HL Morris ML Efler SM Adhami MA Krieg AM Cameron DW Heathcote J CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind phase I/II study J Clin Immunol 2004, 24:693-701. 10.1007/s10875-004-6244-3 15622454
44. Halperin SA Van Nest G Smith B Abtahi S Whiley H Eiden JJ A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant Vaccine 2003, 21:2461-2467. 10.1016/S0264-410X(03)00045-8 12744879
45. Cooper CL Davis HL Angel JB Morris ML Elfer SM Seguin I Krieg AM Cameron DW CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults Aids 2005, 19:1473-1479. 10.1097/01.aids.0000183514.37513.d2 16135900
46. Dzionek A Fuchs A Schmidt P Cremer S Zysk M Miltenyi S Buck DW Schmitz J BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood J Immunol 2000, 165:6037-6046. 11086035
47. Yi AK Hornbeck P Lafrenz DE Krieg AM CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL J Immunol 1996, 157:4918-4925. 8943396
48. Vollmer J Weeratna RD Jurk M Samulowitz U McCluskie MJ Payette P Davis HL Schetter C Krieg AM Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation Immunology 2004, 113:212-223. 1782571 15379982 10.1111/ j.1365-2567.2004.01962.x
49. Fried MW Shiffman ML Reddy KR Smith C Marinos G Goncales FL Jr. Haussinger D Diago M Carosi G Dhumeaux D Craxi A Lin A Hoffman J Yu J Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 2002, 347:975-982. 10.1056/NEJMoa020047 12324553
50. Manns MP McHutchison JG Gordon SC Rustgi VK Shiffman M Reindollar R Goodman ZD Koury K Ling M Albrecht JK Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 2001, 358:958-965. 10.1016/S0140-6736(01)06102-5 11583749
51. Vollmer J Jurk M Samulowitz U Lipford G Forsbach A Wullner M Tluk S Hartmann H Kritzler A Muller C Schetter C Krieg AM CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells J Endotoxin Res 2004, 10:431-438. 15588427
52. Verthelyi D Ishii KJ Gursel M Takeshita F Klinman DM Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs J Immunol 2001, 166:2372-2377. 11160295
53. Anthony DD Yonkers NL Post AB Asaad R Heinzel FP Lederman MM Lehmann PV Valdez H Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection J Immunol 2004, 172:4907-4916. 15067070
54. Longman RS Talal AH Jacobson IM Rice CM Albert ML Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C J Infect Dis 2005, 192:497-503. 10.1086/431523 15995965
55. Ulsenheimer A Gerlach JT Jung MC Gruener N Wachtler M Backmund M Santantonio T Schraut W Heeg MH Schirren CA Zachoval R Pape GR Diepolder HM Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection Hepatology 2005, 41:643-651. 10.1002/hep.20592 15726647
56. Kanto T Inoue M Miyatake H Sato A Sakakibara M Yakushijin T Oki C Itose I Hiramatsu N Takehara T Kasahara A Hayashi N Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection J Infect Dis 2004, 190:1919-1926. 10.1086/425425 15529255
57. Piccioli D Tavarini S Nuti S Colombatto P Brunetto M Bonino F Ciccorossi P Zorat F Pozzato G Comar C Abrignani S Wack A Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors J Hepatol 2005, 42:61-67. 10.1016/ j.jhep.2004.09.014 15629508
58. Goutagny N Fatmi A De Ledinghen V Penin F Couzigou P Inchauspe G Bain C Evidence of viral replication in circulating dendritic cells during hepatitis C virus infection J Infect Dis 2003, 187:1951-1958. 10.1086/ 375350 12792872
59. Murakami H Akbar SM Matsui H Horiike N Onji M Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C Clin Exp Immunol 2004, 137:559-565. 1809147 15320906 10.1111/j.1365-2249.2004.02550.x
60. Szabo G Dolganiuc A Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection Immunobiology 2005, 210:237-247. 10.1016/j.imbio.2005.05.018 16164031
61. Tsubouchi E Akbar SM Horiike N Onji M Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection J Gastroenterol 2004, 39:754-762. 10.1007/ s00535-003-1385-3 15338369
62. Vallin H Perers A Alm GV Ronnblom L Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus J Immunol 1999, 163:6306-6313. 10570325
63. Shevach EM DiPaolo RA Andersson J Zhao DM Stephens GL Thornton AM The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells Immunol Rev 2006, 212:60-73. 10.1111/j.0105-2896.2006.00415.x 16903906